Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells.
1. A method of reducing spinal cord injury-induced parenchymal cavitation in a human subject with an acute spinal cord injury, the method comprising directly injecting into the spinal cord injury site approximately 5 mm caudal of the spinal cord injury epicenter of said subject a composition comprising a population of human pluripotent stem cell-derived oligodendrocyte progenitor cells (OPCs) that are capable of engrafting at the spinal cord injury site and remaining within the spinal cord injury site of said subject for a period of 180 days or longer following the injection.
2. The method according to claim 1 , further comprising administering to the subject a low dose immunosuppressant regimen.
3. The method according to claim 2 , wherein the immunosuppressant regimen comprises a tacrolimus dose of about 0.03 mg/kg/day per os, adjusted to maintain a trough blood concentration of about 3-7 ng/ml through about day 46 following the administering of the composition comprising a population of allogeneically derived OPCs, followed by tapering off and discontinuing the immunosuppressant regimen at about day 60 following the administering of the composition.
4. The method according to claim 1 , wherein the OPCs are capable of remaining within the spinal cord injury site of said subject for a period of about 2 years or longer following the injection of the composition to the spinal cord injury site.
5. The method according to claim 1 , wherein the OPCs are capable of remaining within the spinal cord injury site of said subject for a period of about 3 years or longer following the injection of the composition to the spinal cord injury site.
6. The method according to claim 1 , wherein the OPCs are capable of forming a tissue matrix in the spinal cord injury site of said subject within about 180 days or less, thereby reducing spinal cord injury-induced parenchymal cavitation.
7. The method according to claim 1 , wherein the subject has a thoracic or cervical spinal cord injury.
8. The method according to claim 1 , wherein the composition comprises between about 2×10 6 and 50×10 6 AST-OPC1 cells.
9. The method of claim 1 , wherein the oligodendrocyte progenitor cells are derived from human embryonic stem (hES) cells.
10. The method of claim 1 , wherein the oligodendrocyte progenitor cells are derived from induced pluripotent stem (iPS) cells.